Outlook Therapeutics’ July 16 Shareholder Vote to Decide Nasdaq Fate as FDA Decision Looms on July 29

Outlook Therapeutics enters a high-stakes July with two pivotal events that will shape its future. On the 16th, shareholders must approve a series of capital measures – including a potential reverse stock split – that could determine whether the company retains its Nasdaq listing. Less than two weeks later, on July 29, the FDA is set to rule on the company’s resubmitted application for Lytenava, its experimental treatment for wet age-related macular degeneration.

The stock has recently clawed its way back above the critical $1 threshold, trading at $1.58, after the FDA accepted the Lytenava application for accelerated review. That price is just enough to meet Nasdaq’s minimum bid requirement, but the exchange demands the stock close above $1 for ten consecutive trading days. A failure to maintain that level could trigger delisting, which is why management has put a reverse split – with a ratio of up to 1-to-50 – on the agenda for the extraordinary general meeting.

The shareholder vote on July 16 also includes a proposal to dramatically increase the number of authorized shares to 600 million. That move is designed to give the company flexibility to raise fresh capital through new equity or options, but it will come at a cost to existing holders. The dilution is significant: the issuance of new options alone could bring in roughly $6.1 million while severely watering down current stakes.

Should investors sell immediately? Or is it worth buying Outlook Therapeutics?

The cash crunch is the driving force behind these measures. Outlook ended March with just $7.7 million in cash and equivalents, and an adjusted quarterly loss of $14.1 million highlighted the burn rate. In April, management raised an additional $5 million through a direct stock placement, but according to the company, that still leaves it short of funding for the next twelve months. A sustainable capital injection is urgently needed.

Across the Atlantic, the company is already generating some revenue from Lytenava, which received European approval and recently launched in Germany, Austria, and the United Kingdom. However, first-quarter sales from those markets were modest, offering little near-term relief to the cash-strapped biotech.

The FDA’s decision on July 29 will be the ultimate catalyst. A green light would open the U.S. market and could transform the company’s prospects, while a rejection would likely intensify the financial pressure. For now, all eyes are on the shareholder vote first. If the capital measures pass, the company buys itself the breathing room – and the Nasdaq listing – needed to reach that pivotal regulatory verdict.